.png){kind=icon}
.png){kind=icon}
Return
Low-dose bevacizumab plus atezolizumab enhances transarterial chemoembolization in HCC via correcting vascular-immune niche dysfunction
.png){kind=icon}
PRE
AI
C
H
Z
H
L
Z
K
Y
Z
T
M
Y
L
M
DOI：10.1016/j.jhep.2026.07.028.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• TACE induces a hypoxic vascular niche featuring immature vasculature and an immunosuppressive TME. • TACE enriches PDGFC+ TAMs with pro-angiogenic and immunosuppressive phenotypes, linked to poor prognosis. • PDGFC+ TAMs orchestrate a positive feedback loop of pericyte-to-CAF transition and CAF activation. • Low-dose bevacizumab plus atezolizumab promotes vascular normalization and antitumor immunity after TACE.
Journal
IF:
33
Papers:
3.2W
Citations:
6.5W
Organization
Cited Papers